Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence,natural history and treatment response |
| |
| Authors: | Andrew C. Dietz Todd E. DeFor Claudio G. Brunstein John E. Wagner Jr |
| |
| Affiliation: | 1. Division of Hematology Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Rady Children's Hospital, University of California San Diego, , San Diego, CA, USA;2. Blood and Marrow Transplant Program, University of Minnesota, , Minneapolis, MN, USA;3. Department of Medicine, University of Minnesota, , Minneapolis, MN, USA;4. Department of Pediatrics, University of Minnesota, , Minneapolis, MN, USA |
| |
| Abstract: | Donor‐derived myelodysplastic syndrome/acute leukaemia (DD‐MDS/AL) is a rare life‐threatening complication of allogeneic haematopoietic stem cell (HSC) transplantation. However, it is unknown whether the risk differs by HSC source. Therefore, we evaluated the incidence of DD‐MDS/AL in 2390 engrafted patients. With a median follow‐up of 7·1 years (1–20·8), the incidence of DD‐MDS/AL was 0·53% (95% confidence interval (CI), 0·01–1·41%], 0·56% (95%CI, 0·01–1·36%) and 0·56% (95%CI, 0·01–1·10%) in recipients of bone marrow (n = 1117), peripheral blood (n = 489) and umbilical cord blood (UCB, n = 784), respectively. While follow‐up is shorter in recipients of UCB and peripheral blood, incidence of DD‐MDS/AL is, thus far, similar between HSC sources. |
| |
| Keywords: | donor‐derived leukaemia haematopoietic cell transplantation |
|
|
